Fewer abicipar shots noninferior to monthly ranibizumab injections in nAMD treatment
02 May 2020
bởiJairia Dela Cruz
For patients with neovascular age-related macular degeneration (nAMD), a less frequent dosing regimen of abicipar appears to improve and stabilize visual acuity over 52 weeks of treatment, and this effect is noninferior to that of monthly ranibizumab injections, as shown in the results of two phase III trials.